Carson Wealth (CWM LLC)
CRVS icon

Carson Wealth (CWM LLC)’s Corvus Pharmaceuticals CRVS Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1K Buy
1,237
+1,032
+503% +$16.5K ﹤0.01% 4474
2025
Q4 		$2K Buy
205
+148
+260% +$1.17K ﹤0.01% 5068
2025
Q3 		$0 Buy
+57
New +$292 ﹤0.01% 5309

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Carson Wealth (CWM LLC)'s CRVS Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Corvus Pharmaceuticals (CRVS) stake by 503% in Q1 2026, buying an estimated $16.5K and bringing the position to 1,237 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4474.

Carson Wealth (CWM LLC) first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Carson Wealth (CWM LLC) held 1,237 shares of Corvus Pharmaceuticals worth $18.1K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 1,032 Corvus Pharmaceuticals shares in Q1 2026, an estimated $16.5K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #4474 holding.
  • Carson Wealth (CWM LLC) first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.